Skip to main
WVE
WVE logo

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

WAVE Life Sciences Ltd is experiencing a positive outlook due to a notable increase in the probability of success (POS) for its therapeutic candidates from 10% to 30%, reflecting confidence in the effectiveness of its RNA medicines platform, PRISM. The company has demonstrated promising clinical results, including significant reductions in serum Activin E levels, indicating the potential for sustainable dosing regimens that enhance efficacy while simplifying treatment protocols. Additionally, the ongoing studies suggest the capability of its therapies to address both rare and prevalent diseases with favorable safety profiles, bolstering confidence in the company's growth trajectory and long-term value.

Bears say

WAVE Life Sciences faces a negative outlook primarily due to significant risks associated with two key clinical programs, WVE-004 and WVE-N531, which could hinder regulatory approval and impact future revenue growth. Additionally, the challenging financing environment in the biotechnology sector raises concerns regarding the company's ability to fund product launches effectively, particularly for WVE-N531. Compounded by potential safety and efficacy issues that could arise unexpectedly, these factors create substantial uncertainty around WAVE's future financial performance and market penetration.

WVE has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences (WVE) Forecast

Analysts have given WVE a Buy based on their latest research and market trends.

According to 13 analysts, WVE has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences (WVE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.